Author Correction: Wogonin suppresses osteopontin expression in adipocytes by activating PPARα (Acta Pharmacologica Sinica, (2015), 36, 8, (987-997), 10.1038/aps.2015.37);Wogonin suppresses osteopontin expression in adipocytes by activating PPARα

Acta Pharmacologica Sinica

Volumn 36, Issue 8, 2015, Pages 987-997

  Zhang, Ye Min ^a   Li, Ming Xin ^a   Tang, Zhao ^a   Wang, Chang Hua ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

adipocytes; osteopontin; p38 MAPK; PPAR ; wogonin

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; DEXAMETHASONE; INSULIN; ISOBUTYLMETHYLXANTHINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN C FOS; PROTEIN C JUN; STREPTOZOCIN; WOGONIN; FLAVANONE DERIVATIVE; HERBACEOUS AGENT; SMALL INTERFERING RNA;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROADIPOCYTE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UPREGULATION; WESTERN BLOTTING; 3T3 CELL LINE; AGONISTS; ANIMAL; C57BL MOUSE; CHEMISTRY; COMPLICATION; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GENETICS; HYPERGLYCEMIA; METABOLISM; PHOSPHORYLATION; RNA INTERFERENCE; SCUTELLARIA;

3T3-L1 CELLS; ANIMALS; DIABETES MELLITUS, TYPE 1; DOWN-REGULATION; DRUGS, CHINESE HERBAL; FLAVANONES; HYPERGLYCEMIA; MICE; MICE, INBRED C57BL; OSTEOPONTIN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PPAR ALPHA; RNA INTERFERENCE; RNA, SMALL INTERFERING; SCUTELLARIA;

EID: 84938776577     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/s41401-022-01034-x     Document Type: Erratum

References (45)

1. Singh M, Dalal S, Singh K. Osteopontin: at the cross-roads of myocyte survival and myocardial function. Life Sci 2014; 118: 1-6
2. Wolak T. Osteopontin-A multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis 2014; 236: 327-37
3. Bandopadhyay M, Bulbule A, Butti R, Chakraborty G, Ghorpade P, Ghosh P, et al. Osteopontin as a therapeutic target for cancer. Expert Opin Ther Targets 2014; 18: 883-95
4. Inoue M, Shinohara ML. Intracellular osteopontin (iOPN) and immunity. Immunol Res 2011; 49: 160-72
5. Kahles F, Findeisen HM, Bruemmer D. Osteopontin: a novel regulator at the cross roads of inflammation, obesity and diabetes. Mol Metab 2014; 3: 384-93
6. Kiefer FW, Neschen S, Pfau B, Legerer B, Neuhofer A, Kahle M, et al. Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia 2011; 54: 2132-42
7. Kiefer FW, Zeyda M, Gollinger K, Pfau B, Neuhofer A, Weichhart T, et al. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 2010; 59: 935-46
8. Chapman J, Miles PD, Ofrecio JM, Neels JG, Yu JG, Resnik JL, et al. Osteopontin is required for the early onset of high fat diet-induced insulin resistance in mice. PLoS One 2010; 5: e13959
9. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood EB, et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest 2007; 117: 2877-88
10. Chirumbolo S. Anticancer properties of the flavone wogonin. Toxicology 2013; 314: 60-4
11. Li-Weber M. New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev 2009; 35: 57-68
12. Lee SO, Jeong YJ, Yu MH, Lee JW, Hwangbo MH, Kim CH, et al. Wogonin suppresses TNF-Alpha-induced MMP-9 expression by blocking the NF-kappaB activation via MAPK signaling pathways in human aortic smooth muscle cells. Biochem Biophys Res Commun 2006; 351: 118-25
13. Chang YL, Shen JJ, Wung BS, Cheng JJ, Wang DL. Chinese herbal remedy wogonin inhibits monocyte chemotactic protein-1 gene expression in human endothelial cells. Mol Pharmacol 2001; 60: 507-13
14. Liu YM, Wang X, Nawaz A, Kong ZH, Hong Y, Wang CH, et al. Wogonin ameliorates lipotoxicity-induced apoptosis of cultured vascular smooth muscle cells via interfering with DAG-PKC pathway. Acta Pharmacol Sin 2011; 32: 1475-82
15. Bak EJ, Kim J, Choi YH, Kim JH, Lee DE, Woo GH, et al. Wogonin ameliorates hyperglycemia and dyslipidemia via PPAR? activation in db/db mice. Clin Nutr 2014; 33: 156-63
16. Huynh K, Kiriazis H, Du XJ, Love JE, Gray SP, Jandeleit-Dahm KA, et al. Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice. Free Radic Biol Med 2013; 60: 307-17
17. Bai Y, Cui W, Xin Y, Miao X, Barati MT, Zhang C, et al. Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J Mol Cell Cardiol 2013; 57: 82-95
18. Qi Q, Peng J, Liu W, You Q, Yang Y, Lu N, et al. Toxicological studies of wogonin in experimental animals. Phytother Res 2009; 23: 417-22
19. Sun S, Liu Y, Lu J, Omar A, Sun S, Bi Y, et al. The inhibitory effects of PKC? on adiponectin expression is mediated by ERK in 3T3-L1 adipocytes. J Endocrinol Invest 2011; 34: 8-15
20. Wang X, Yu W, Nawaz A, Guan F, Sun S, Wang C. Palmitate induced insulin resistance by PKCtheta-dependent activation of mTOR/S6K pathway in C2C12 myotubes. Exp Clin Endocrinol Diabetes 2010; 118: 657-61
21. Diradourian C, Le May C, Caüzac M, Girard J, Burnol AF, Pégorier JP. Involvement of ZIP/p62 in the regulation of PPARalpha transcriptional activity by p38-MAPK. Biochim Biophys Acta 2008; 1781: 239-44
22. Nakamachi T, Nomiyama T, Gizard F, Heywood EB, Jones KL, Zhao Y, et al. PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. Diabetes 2007; 56: 1662-70
23. Li CB, Li XX, Chen YG, Zhang C, Zhang MX, Zhao XQ, et al. Effects and mechanisms of PPARalpha activator fenofibrate on myocardial remodelling in hypertension. J Cell Mol Med 2009; 13: 4444-52
24. Rochette L, Zeller M, Cottin Y, Vergely C. Diabetes, oxidative stress and therapeutic strategies. Biochim Biophys Acta 2014; 1840: 2709-29
25. Fernández-García JC, Cardona F, Tinahones FJ. Inflammation, oxidative stress and metabolic syndrome: dietary modulation. Curr Vasc Pharmacol 2013; 11: 906-19
26. Lee YM, Cheng PY, Chen SY, Chung MT, Sheu JR. Wogonin suppresses arrhythmias, inflammatory responses, and apoptosis induced by myocardial ischemia/reperfusion in rats. J Cardiovasc Pharmacol 2011; 58: 133-42
27. Huang WH, Lee AR, Yang CH. Antioxidative and anti-inflammatory activities of polyhydroxyflavonoids of Scutellaria baicalensis GEORGI. Biosci Biotechnol Biochem 2006; 70: 2371-80
28. Zeyda M, Gollinger K, Todoric J, Kiefer FW, Keck M, Aszmann O, et al. Osteopontin is an activator of human adipose tissue macrophages and directly affects adipocyte function. Endocrinology 2011; 152: 2219-27
29. Katakam AK, Chipitsyna G, Gong Q, Vancha AR, Gabbeta J, Arafat HA. Streptozotocin (STZ) mediates acute upregulation of serum and pancreatic osteopontin (OPN): a novel islet-protective effect of OPN through inhibition of STZ-induced nitric oxide production. J Endocrinol 2005; 187: 237-47
30. Kawamura H, Yokote K, Asaumi S, Kobayashi K, Fujimoto M, Maezawa Y, et al. High glucose-induced upregulation of osteopontin is mediated via Rho/Rho kinase pathway in cultured rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2004; 24: 276-81
31. Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, et al. Peroxisome proliferator-Activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 2005; 54: 3358-70
32. Guzmán M, Lo Verme J, Fu J, Oveisi F, Blázquez C, Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-Activated receptor alpha (PPAR-Alpha). J Biol Chem 2004; 279: 27849-54
33. Hu Y, Chen Y, Ding L, He X, Takahashi Y, Gao Y, et al. Pathogenic role of diabetes-induced PPAR-? down-regulation in microvascular dysfunction. Proc Natl Acad Sci U S A 2013; 110: 15401-6
34. Barger PM, Browning AC, Garner AN, Kelly DP. p38 Mitogen-Activated protein kinase activates peroxisome proliferator-Activated receptor alpha: a potential role in the cardiac metabolic stress response. J Biol Chem 2001; 276: 44495-501
35. Lu N, Gao Y, Ling Y, Chen Y, Yang Y, Gu HY, et al. Wogonin suppresses tumor growth in vivo and VEGF-induced angiogenesis through inhibiting tyrosine phosphorylation of VEGFR2. Life Sci 2008; 82: 956-63
36. Carlson CJ, Koterski S, Sciotti RJ, Poccard GB, Rondinone CM. Enhanced basal activation of mitogen-Activated protein kinases in adipocytes from type 2 diabetes: potential role of p38 in the downregulation of GLUT4 expression. Diabetes 2003; 52: 634-41
37. Rajasekar N, Dwivedi S, Nath C, Hanif K, Shukla R. Protection of streptozotocin induced insulin receptor dysfunction, neuroinflammation and amyloidogenesis in astrocytes by insulin. Neuropharmacology 2014; 86: 337-52
38. Taniguchi K, Xia L, Goldberg HJ, Lee KW, Shah A, Stavar L, et al. Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice. Diabetes 2013; 62: 3874-86
39. Gao P, Wu X, Shui H, Jia R. Fluvastatin inhibits high glucose-induced nuclear factor kappa B activation in renal tubular epithelial cells. J Nephrol 2013; 26: 289-96
40. Sharma R, Buras E, Terashima T, Serrano F, Massaad CA, Hu L, et al. Hyperglycemia induces oxidative stress and impairs axonal transport rates in mice. PLoS One 2010; 5: e13463
41. Sodhi CP, Phadke SA, Batlle D, Sahai A. Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells: potentiation by high glucose. Diabetes 2001; 50: 1482-90
42. Bertola A, Deveaux V, Bonnafous S, Rousseau D, Anty R, Wakkach A, et al. Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes 2009; 58: 125-33
43. Gómez-Ambrosi J, Catalán V, Ramírez B, Rodríguez A, Colina I, Silva C, et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab 2007; 92: 3719-27
44. You JS, Ji HI, Chang KJ, Yoo MC, Yang HI, Jeong IK, et al. Serum osteopontin concentration is decreased by exercise-induced fat loss but is not correlated with body fat percentage in obese humans. Mol Med Rep 2013; 8: 579-84
45. Ahmad R, Al-Mass A, Al-Ghawas D, Shareif N, Zghoul N, Melhem M, et al. Interaction of osteopontin with IL-18 in obese individuals: implications for insulin resistance. PLoS One 2013; 8: e63944